![Daniel Char](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Char
General Counsel at
QUANTERIX CORPORATION
Profile
Daniel S.
Char is Secretary & Chief Legal Officer at Quanterix Corp.
since 2025.
Formerly, Mr. Char was Associate General Counsel at Biogen, Inc. from 1995 to 2006, Senior Associate General Counsel at Idenix Pharmaceuticals LLC from 2006 to 2007, Secretary, Vice President & General Counsel at Targanta Therapeutics Corp.
from 2008 to 2009, Associate General Counsel-Commercial at Smith + Nephew, Inc. from 2009 to 2018, Chief Legal Officer & Senior Vice President at ImmunoGen, Inc., Secretary & General Counsel at Evelo Biosciences, Inc. from 2018 to 2022, and Chief Legal Officer at Oculis Holding AG from 2024 to 2025.
Education includes an undergraduate degree from Tufts University in 1983 and a graduate degree from Harvard Law School in 1986.
Daniel Char active positions
| Companies | Position | Start |
|---|---|---|
| QUANTERIX CORPORATION | General Counsel | 2025-11-30 |
Former positions of Daniel Char
| Companies | Position | End |
|---|---|---|
| OCULIS HOLDING AG | General Counsel | 2024-12-31 |
| EVELO BIOSCIENCES, INC. | General Counsel | 2021-12-31 |
Smith + Nephew, Inc.
 Smith + Nephew, Inc. Medical SpecialtiesHealth Technology Develops and markets medical devices | Corporate Officer/Principal | 2018-02-28 |
Targanta Therapeutics Corp.
 Targanta Therapeutics Corp. BiotechnologyHealth Technology Discovers and develops novel antibacterial pro drugs | General Counsel | 2009-02-28 |
| IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 2006-12-31 |
Training of Daniel Char
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
91
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for the treatment of human viral and infectious diseases caused by hepatitis | Health Technology |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Discovers and develops novel antibacterial pro drugs | Health Technology |
Quanterix Corp.
 Quanterix Corp. Medical SpecialtiesHealth Technology Develops and sells protein biomarker instruments that identify signatures in blood & tissue to provide insights to providers, patients and research organizations | Health Technology |
Smith + Nephew, Inc.
Smith + Nephew, Inc. Medical SpecialtiesHealth Technology Develops and markets medical devices | Health Technology |
Tufts University
 Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Law School
 Harvard Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Evelo Biosciences, Inc.
 Evelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for small intestine related diseases | Health Technology |
Oculis Holding AG
 Oculis Holding AG Miscellaneous Commercial ServicesCommercial Services Operates as a global biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases | Commercial Services |
- Stock Market
- Insiders
- Daniel Char
